Wojciech Krzyzanski
Overview
Explore the profile of Wojciech Krzyzanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1014
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan X, Krzyzanski W, Wong R, Liu D, Yan X
ACS Pharmacol Transl Sci
. 2023 Dec;
6(12):1884-1897.
PMID: 38093847
Chemotherapy-induced anemia and thrombocytopenia (CIAT) in cancer patients are often caused by the damage of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. We have previously shown that...
2.
Krzyzanski W, Wintermark P, Annaert P, Groenendaal F, Sahin S, Oncel M, et al.
AAPS J
. 2023 Dec;
26(1):4.
PMID: 38051395
The objective was to apply a population model to describe the time course and variability of serum creatinine (sCr) in (near)term neonates with moderate to severe encephalopathy during and after...
3.
Krzyzanski W, Bauer R
J Pharm Sci
. 2023 Nov;
113(1):257-267.
PMID: 37926235
Objectives: Cell trafficking encompasses movement of the immune system cells (e.g., granulocytes, lymphocytes) between the blood and the extravascular tissues (e.g., lymph nodes). Corticosteroids are known to suppress cell trafficking....
4.
Krzyzanski W, Milad M, Jobe A, Jusko W
CPT Pharmacometrics Syst Pharmacol
. 2023 Mar;
12(5):668-680.
PMID: 36917704
Minimal physiologically-based pharmacokinetic (mPBPK) models are an alternative to full physiologically-based pharmacokinetic (PBPK) models as they offer reduced complexity while maintaining the physiological interpretation of key model components. Full PBPK...
5.
Fan X, Krzyzanski W, Liu D, Wong R, Yan X
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839666
Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of anemia in patients with chronic kidney disease. However, EPO-resistance is an important contributor to the...
6.
Krzyzanski W, Stockard B, Gaedigk A, Scott A, Nolte W, Gibson K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Oct;
12(1):110-121.
PMID: 36309972
Indomethacin is used commonly in preterm neonates for the prevention of intracranial hemorrhage and closure of an abnormally open cardiac vessel. Due to biomedical advances, the infants who receive this...
7.
Ren T, Zhu X, Jusko N, Krzyzanski W, Jusko W
J Pharmacokinet Pharmacodyn
. 2022 Aug;
49(5):493-510.
PMID: 36040645
Therapeutic responses of most drugs are initiated by the rate and degree of binding to their receptors or targets. The law of mass action describes the rate of drug-receptor complex...
8.
Xu P, Wong R, Krzyzanski W, Yan X
Front Pharmacol
. 2022 May;
13:876573.
PMID: 35517793
Erythroferrone (ERFE) is a hormone identified recently as a master regulator connecting iron homeostasis and erythropoiesis. Serum ERFE concentrations significantly increase in animals and humans with normal or impaired kidney...
9.
Fan X, Krzyzanski W, Wong R, Yan X
J Pharmacol Exp Ther
. 2022 Apr;
382(1):31-43.
PMID: 35489782
Erythropoietin (EPO) and thrombopoietin (TPO) have long been known to promote erythropoiesis and megakaryopoiesis, respectively. However, the fate-changing role of EPO and TPO on megakaryocyte-erythroid progenitors (MEPs) to develop along...
10.
Yan X, Bauer R, Koch G, Schropp J, Perez Ruixo J, Krzyzanski W
J Pharmacokinet Pharmacodyn
. 2021 Jul;
48(6):763-802.
PMID: 34302262
Delay differential equations (DDEs) are commonly used in pharmacometric models to describe delays present in pharmacokinetic and pharmacodynamic data analysis. Several DDE solvers have been implemented in NONMEM 7.5 for...